IFNB1 and neoplasm: Studies using rAd-IFNβ demonstrated disease control in 30% of patients (3 out of 10 subjects) [171], tumor stabilization or regression in 40% of cases (4 out of 10 patients) [168], and a temporary positive response in one patient followed by subsequent tumor progression [176].